Figure 4
Effect of 5-lipoxygenase (5-LO) inhibition by MK-886 on portal perfusion pressure and liver injury following KC activation. Data are expressed as the mean±s.d. (a) Activation of KC by Zymosan infusion (Zy, 150 μg/ml, from 40 to 46 min after starting liver perfusion) of sham-operated livers and of cholestatic livers (each n=6) in addition to treatment with the solvent DMSO (20–50 min) was accompanied by a marked increase in portal perfusion pressure (*P<0.05). The inhibition of 5-LO activation by the infusion of MK-886 (3 μM, n=6) from 20 to 50 min significantly (#P<0.05) reduced this maximal increase in portal perfusion pressure after KC activation by Zymosan (150 μg/ml) in both settings (n=6). (b) In sham-operated livers, the infusion of Zymosan (150 μg/ml) from 40 to 46 min after starting liver perfusion in addition to treatment with the solvent DMSO (2050 min) increased LDH efflux as a sign of cell damage. One week after bile duct ligation, the infusion of Zymosan (150 μg/ml) from 40 to 46 min after starting liver perfusion in addition to treatment with the solvent DMSO enhanced the increase in LDH efflux as well (n=6) (*P<0.05). This LDH efflux was significantly attenuated by MK-886 treatment (3 μM, 20–50 min, n=6, #P<0.05).
